Elicera Therapeutics AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Net Income	-18.75	-16.11	-16.4	-19.44	-13.12	-2.82	Upgrade
Depreciation & Amortization	0.01	0.01	0.01	0.01	0.01	0.01	Upgrade
Other Operating Activities	-	-	0	0	-	0	Upgrade
Change in Accounts Payable	1.37	1.16	0.15	-1.32	0.1	1.95	Upgrade
Change in Other Net Operating Assets	2.43	-8.53	1.31	12.17	-1.28	-0.05	Upgrade
Operating Cash Flow	-14.94	-23.46	-14.92	-8.57	-14.29	-0.91	Upgrade
Sale (Purchase) of Intangibles	-	-	-0	-	-	-0.06	Upgrade
Investment in Securities	0	-	0.48	-	-0	0.05	Upgrade
Investing Cash Flow	0	-	0.48	-	-0	-0.01	Upgrade
Issuance of Common Stock	22.03	27.56	-	-	62	12.45	Upgrade
Other Financing Activities	-2.14	-7.08	-	-	-6.88	-	Upgrade
Financing Cash Flow	19.89	20.48	-	-	55.12	12.45	Upgrade
Net Cash Flow	4.95	-2.98	-14.44	-8.57	40.83	11.53	Upgrade
Cash Interest Paid	0.02	0.05	0.08	0.13	0	-	Upgrade
Cash Income Tax Paid	-	-	-	-0	-	-	Upgrade
Levered Free Cash Flow	-8.4	-17.94	-9.26	-1.32	-9.37	0.09	Upgrade
Unlevered Free Cash Flow	-8.39	-17.91	-9.21	-1.24	-9.37	0.09	Upgrade
Change in Net Working Capital	-3.8	7.36	-1.46	-10.85	1.18	-1.91	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.